Ocular implant containing bevacizumab-loaded chitosan nanoparticles intended for choroidal neovascularization treatment

被引:46
|
作者
Badiee, Parisa [1 ]
Varshochian, Reyhaneh [1 ,2 ]
Rafiee-Tehrani, Morteza [1 ,2 ]
Dorkoosh, Farid Abedin [1 ]
Khoshayand, Mohammad Reza [3 ]
Dinarvand, Rassoul [1 ,2 ]
机构
[1] Univ Tehran Med Sci, Dept Pharmaceut, Fac Pharm, Tehran 1417614411, Iran
[2] Univ Tehran Med Sci, Nanotechnol Res Ctr, Fac Pharm, Tehran 1417614411, Iran
[3] Univ Tehran Med Sci, Dept Drug & Food Control, Fac Pharm, Tehran 1417614411, Iran
关键词
bevacizumab; chitosan nanoparticles; hyaluronic acid implant; nanoparticle optimization; ocular drug delivery; DRUG-DELIVERY SYSTEMS; PROTEIN DELIVERY; MACULAR DEGENERATION; PLGA NANOPARTICLES; CONTROLLED-RELEASE; PHARMACOKINETICS; EYE; OPTIMIZATION; ALBUMIN; RANIBIZUMAB;
D O I
10.1002/jbm.a.36424
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Choroidal neovascularization (CNV) is among the leading causes of blindness worldwide. Bevacizumab has demonstrated promising effects on CNV treatment; however, frequent intravitreal injection is its major drawback. Current study aimed to address this issue by developing a sustained release formulation through nanoparticles of bevacizumab imbedded in an ocular implant. Bevacizumab-loaded chitosan nanoparticles were prepared by ionic gelation method and inserted in the matrix of hyaluronic acid and zinc sulfate. Despite the common approaches in using ultraviolet (UV)-spectrophotometry, microprotein-Bradford, and bicinchoninic acid (BCA), assay for protein assessment, our results revealed a remarkable UV-Vis absorption overlap of protein and chitosan during these analysis and thus enzyme-linked immunosorbent assay was employed for the antibody concentration assay. The size of optimized nanoparticles obtained through statistical analysis based on design of experiments was 78.5 +/- 1.9 nm with polydispersity index of 0.13 +/- 0.05 and the entrapment-efficiency and loading-efficiency were 67.6 +/- 6.7 and 15.7 +/- 5.7%, respectively. The scanning electron microscopy and confocal microscopy images revealed a homogenous distribution of nanoparticles in the implant matrix and the release test results indicated an appropriate extended release of bevacizumab from the carrier over two months. In conclusion, the prepared system provided a sustained release bevacizumab delivery formulation which can introduce a promising ocular drug delivery system intended for posterior segment disease. (c) 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 2261-2271, 2018.
引用
收藏
页码:2261 / 2271
页数:11
相关论文
共 50 条
  • [31] Intravitreal Bevacizumab as a Primary Treatment for Idiopathic Choroidal Neovascularization
    Cheema, Rizwan A.
    Mushtaq, Javed
    Cheema, Maheera A.
    MIDDLE EAST AFRICAN JOURNAL OF OPHTHALMOLOGY, 2011, 18 (03) : 220 - 223
  • [32] Bevacizumab for treatment of choroidal neovascularization secondary to candida chorioretinitis
    Georgios Makragiannis
    Kaveh Vahdani
    Ester Carreño
    Richard W. J. Lee
    Andrew D. Dick
    Adam H. Ross
    International Ophthalmology, 2018, 38 : 781 - 785
  • [33] Treatment outcomes of choroidal neovascularization secondary to ocular histoplasmosis
    Comer, GM
    Ciulla, TA
    Gao, H
    Maturi, K
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46
  • [34] Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
    Wang, Jia-Kang
    Huang, Tzu-Lun
    Chang, Pei-Yao
    Chen, Yen-Ting
    Chang, Chin-Wei
    Chen, Fang-Ting
    Hsu, Yung-Ray
    Chen, Yun-Ju
    SCIENTIFIC REPORTS, 2018, 8
  • [35] Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to angioid streaks
    Apte, R. S.
    EYE, 2008, 22 (05) : 734 - 735
  • [36] Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia
    Rheaume, Marc-Andre
    Sebag, Mikael
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2008, 43 (05): : 576 - 580
  • [37] Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
    Jia-Kang Wang
    Tzu-Lun Huang
    Pei-Yao Chang
    Yen-Ting Chen
    Chin-Wei Chang
    Fang-Ting Chen
    Yung-Ray Hsu
    Yun-Ju Chen
    Scientific Reports, 8
  • [38] Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to pseudotumor cerebri
    Jamerson S.C.
    Arunagiri G.
    Ellis B.D.
    Leys M.J.
    International Ophthalmology, 2009, 29 (3) : 183 - 185
  • [39] INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO ANGIOID STREAKS
    Kakade, Sathya J.
    Bhajantri, Manoj
    Muralidharakrishna
    JOURNAL OF EVOLUTION OF MEDICAL AND DENTAL SCIENCES-JEMDS, 2013, 2 (43): : 8324 - 8327
  • [40] Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization
    Mandal, S.
    Venkatesh, P.
    Sampangi, R.
    Garg, S.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2007, 17 (04) : 620 - 626